Covaxin Neutralises Double Mutant Strain: ICMR

April 21, 2021

Covaxin, the Made-in-India COVID-19 vaccine, neutralises multiple variants of SARS-CoV-2 and it is also effective against the double mutant strain.

This was said by the Indian Council of Medical Research (ICMR) on April 21.

"ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well," the ICMR tweeted.

It may be mentioned here that ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant).

ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant, the top health research body said.

ICMR-NIV recently has been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 identified in certain regions of India and several other countries, the ICMR stated.

It may be further mentioned here that Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the world with another 60 in the process.

"Covaxin has been found to effectively neutralise the double mutant strain as well," the ICMR tweeted.

The vaccine is being made by Bharat Biotech.

Share article on:

Developed By Lumenoid Studios
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram